公开(公告)号：US20170243740A1

公开(公告)日：2017-08-24

申请号：US15511911

申请日：2015-09-25

申请人： Philipps-Universität Marburg

发明人： Carsten VON HAENISCH ,  Kerstin VOLZ ,  Wolfgang STOLZ ,  Eduard STERZER ,  Andreas BEYER ,  Dominik KEIPER ,  Benjamin RINGLER

IPC分类号： H01L21/02 ,  C07F9/50 ,  C07F9/90 ,  C23C16/22 ,  C07F9/72

CPC分类号： H01L21/02538 ,  C07F9/46 ,  C07F9/504 ,  C07F9/72 ,  C07F9/90 ,  C23C16/22 ,  C23C16/301 ,  H01L21/0254 ,  H01L21/02543 ,  H01L21/02546 ,  H01L21/02549 ,  H01L21/0262

摘要： The invention provides the use of at least one binary group 15 element compound of the general formula R1R2E-E′R3R4 (I) or R5E(E′R6R7)2 (II) as the educt in a vapor deposition process. In this case, R1, R2, R3 and R4 are independently selected from the group consisting of H, an alkyl radical (C1-C10) and an aryl group, and E and E′ are independently selected from the group consisting of N, P, As, Sb and Bi. This use excludes hydrazine and its derivatives. The binary group 15 element compounds according to the invention allow the realization of a reproducible production and/or deposition of multinary, homogeneous and ultrapure 13/15 semiconductors of a defined combination at relatively low process temperatures. This makes it possible to completely waive the use of an organically substituted nitrogen compound such as 1.1 dimethyl hydrazine as the nitrogen source, which drastically reduces nitrogen contaminations—compared to the 13/15 semiconductors and/or 13/15 semiconductor layers produced with the known production methods.

公开(公告)号：US08865764B2

公开(公告)日：2014-10-21

申请号：US13676929

申请日：2012-11-14

申请人： ZIOPHARM Oncology, Inc.

发明人： Paul Gutsch ,  Brian Renzelmann

IPC分类号： A61K45/06 ,  C07F9/72 ,  A61K31/285

CPC分类号： A61K45/06 ,  A61K31/285 ,  C07F9/72

摘要： The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.

摘要翻译： 本发明提供有机砷。 许多这些化合物对许多人类肿瘤细胞系（包括固体和血液来源）以及来自患有白血病的患者的恶性血细胞具有有效的体外细胞毒活性。

公开(公告)号：US20140220115A1

公开(公告)日：2014-08-07

申请号：US14246678

申请日：2014-04-07

申请人： Northwestern University

发明人： Thomas V. O'Halloran ,  Haimei Chen ,  Andrew Mazar

IPC分类号： A61K9/127 ,  C07F15/00 ,  C07F9/72 ,  A61K31/282

CPC分类号： A61K9/127 ,  A61K9/1271 ,  A61K31/282 ,  A61K33/24 ,  A61K33/36 ,  A61K38/193 ,  A61K38/40 ,  A61K45/06 ,  A61K47/6913 ,  C07F9/72 ,  C07F15/0093 ,  C07K16/2887 ,  C07K2317/24 ,  A61K2300/00

摘要： The present invention relates to nanoparticle encapsulated arsenic and platinum compositions and methods of use thereof. In particular, the present invention provides co-encapsulation of active forms of arsenic and platinum drugs into liposomes, and methods of using such compositions for the diagnosis and treatment of cancer.

摘要翻译： 本发明涉及纳米颗粒包封的砷和铂组合物及其使用方法。 特别地，本发明提供了活性形式的砷和铂药物到脂质体中的共包封，以及使用这些组合物来诊断和治疗癌症的方法。

公开(公告)号：US20100228073A1

公开(公告)日：2010-09-09

申请号：US12309992

申请日：2007-11-28

申请人： Koichiro Nakamura ,  Akihiro Hishinuma ,  Shinji Kamiya

发明人： Koichiro Nakamura ,  Akihiro Hishinuma ,  Shinji Kamiya

IPC分类号： A62D3/37

CPC分类号： A62D3/38 ,  A62D3/33 ,  A62D3/36 ,  A62D3/37 ,  A62D2101/02 ,  A62D2101/24 ,  A62D2203/04 ,  C07F9/72

摘要： It is an object of the present invention to provide a method of detoxifying a methyl compound comprising arsenic etc., effectively and systematically. The method of detoxifying a methyl compound according to the present invention is characterized in that an organic halogenated compound is reacted with a methyl compound comprising at least one element selected from the groups comprising arsenic, antimony and selenium to convert the methyl compound into more harmless substances. Furthermore, in a preferred embodiment of the method of detoxifying a methyl compound according to the present invention, the method is characterized in that the element is arsenic.

摘要翻译： 本发明的目的是提供一种有效和系统地对包含砷等的甲基化合物进行解毒的方法。 根据本发明的甲基化合物的解毒方法的特征在于，有机卤代化合物与包含至少一种选自砷，锑和硒的元素的甲基化合物反应，以将甲基化合物转化为更无害的物质 。 此外，在根据本发明的甲基化合物的解毒方法的优选实施方案中，该方法的特征在于该元素是砷。

公开(公告)号：US20090233894A1

公开(公告)日：2009-09-17

申请号：US12087682

申请日：2007-01-16

申请人： Ralph A. Zingaro

发明人： Ralph A. Zingaro

IPC分类号： A61K31/285 ,  C07F9/72 ,  A61P35/00 ,  C07F9/82

CPC分类号： A61K31/285 ,  A61K31/203 ,  A61K31/555 ,  A61K45/06 ,  A61K48/00 ,  C07F9/72 ,  C07F9/82

摘要： The present invention provides organic arsenicals which may be used to treat numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.

摘要翻译： 本发明提供有机砷，其可用于治疗来自固体和血液来源的多种人类肿瘤细胞系，以及来自白血病患者的恶性血细胞。

公开(公告)号：US07405314B2

公开(公告)日：2008-07-29

申请号：US11252966

申请日：2005-10-17

申请人： Ralph A. Zingaro ,  Hatice Duzkale ,  Emil J. Freireich ,  Hagop Kantarjian ,  Merida Sotelo-Lerma ,  Srdan Verstovsek ,  Mingzhang Gao

发明人： Ralph A. Zingaro ,  Hatice Duzkale ,  Emil J. Freireich ,  Hagop Kantarjian ,  Merida Sotelo-Lerma ,  Srdan Verstovsek ,  Mingzhang Gao

IPC分类号： A61K61/285 ,  C07F9/00

CPC分类号： C07F9/72 ,  C07F9/74

摘要： The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.

公开(公告)号：US07074766B1

公开(公告)日：2006-07-11

申请号：US10088540

申请日：2000-09-20

申请人： Philip John Hogg ,  Neil Donoghue

发明人： Philip John Hogg ,  Neil Donoghue

IPC分类号： A61K38/02 ,  A61K38/06 ,  C07K5/08 ,  C07K9/322

CPC分类号： C07F9/72 ,  C07F9/78 ,  C07F9/80

摘要： The present invention relates to a compound according to Formula (I): A-(L-Y)p, wherein A comprises at least one substantially cell-membrane impermeable pendant group; L comprises any suitable linker and/or spacer group; Y comprises at least one arsenoxide or arsenoxide equivalent; p is an integer from 1 to 10; and the sum total of carbon atoms in A and L together, is greater than 6.

摘要翻译： 本发明涉及式（I）的化合物：A-（L-Y）p，其中A包含至少一个基本上为细胞膜不可渗透的侧基; L包含任何合适的接头和/或间隔基团; Y包含至少一种等同的砷或砷; p是1至10的整数; 并且A和L中的碳原子总数在一起，大于6。

公开(公告)号：US20050245486A1

公开(公告)日：2005-11-03

申请号：US11173055

申请日：2005-07-01

申请人： John Frangioni

发明人： John Frangioni

IPC分类号： C12N9/00 ,  A61K31/66 ,  A61K45/00 ,  A61K51/00 ,  A61P13/08 ,  A61P13/12 ,  A61P15/08 ,  A61P25/00 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00 ,  C07F5/02 ,  C07F9/00 ,  C07F9/22 ,  C07F9/28 ,  C07F9/30 ,  C07F9/32 ,  C07F9/572 ,  C07F9/6596 ,  C07F9/70 ,  C07F9/72 ,  C07H15/252 ,  C07K14/415 ,  C07K14/46 ,  C12N9/10 ,  C12N9/16 ,  C12Q1/04 ,  G01N33/574

CPC分类号： G01N33/57492 ,  C07F5/025 ,  C07F9/005 ,  C07F9/301 ,  C07F9/3211 ,  C07F9/5728 ,  C07F9/6596 ,  C07F9/72 ,  C07H15/252 ,  G01N33/57426 ,  G01N33/57434

摘要： The instant invention provides reagents and methods for diagnosis, detection and treatment of cancers (for example, prostate cancers). In particular, the invention provides methods to generate various functionalized PSMA ligands, and their uses in diagnosis, detection, imaging, and treatment of prostate cancers, especially those overexpressing PSMA.

公开(公告)号：US06911471B2

公开(公告)日：2005-06-28

申请号：US10337969

申请日：2003-01-07

申请人： Ralph A. Zingaro ,  Emil J. Freireich ,  Hatice Duzkale ,  Hagop Kantarjian ,  Srdan Verstovsek ,  Merida Sotelo-Lerma

发明人： Ralph A. Zingaro ,  Emil J. Freireich ,  Hatice Duzkale ,  Hagop Kantarjian ,  Srdan Verstovsek ,  Merida Sotelo-Lerma

IPC分类号： A61K38/00 ,  A61K31/203 ,  A61K31/285 ,  A61P35/00 ,  A61P35/02 ,  C07F9/72 ,  C07F9/74 ,  C07F9/78 ,  A61K33/36 ,  C07F9/70

CPC分类号： C07F9/72

摘要： Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.

摘要翻译： 三氧化二砷（无机化合物）是市售的抗癌剂，但具有显着的毒性。 另一方面，有机砷的毒性远低于体内无机砷甲基化成有机砷被认为是解毒反应的程度。 已经合成了新的有机砷衍生物，包括S-二甲基胂基 - 谷胱甘肽，S-二甲基胂基 - 硫代琥珀酸和S-二甲基胂基 - 硫代苯甲酸，并建立了其对许多人类肿瘤细胞系的有效体外细胞毒活性，包括固体和血液学起源 ，以及来自白血病患者的恶性血细胞。 结果形成了开发S-二甲基胂基 - 谷胱甘肽，S-二甲基胂基 - 硫代琥珀酸，S-二甲基胂基 - 硫代苯甲酸和其他有机砷作为抗癌治疗的基础，将高效率与非常低（如果有的话）毒性相结合 。

公开(公告)号：US20040229845A1

公开(公告)日：2004-11-18

申请号：US10869790

申请日：2004-06-16

申请人： Beth Israel Deaconess Medical Center

发明人： John V. Frangioni

IPC分类号： C07F009/70 ,  A61K031/69 ,  A61K031/66 ,  A61K031/285

CPC分类号： G01N33/57492 ,  C07F5/025 ,  C07F9/005 ,  C07F9/301 ,  C07F9/3211 ,  C07F9/5728 ,  C07F9/6596 ,  C07F9/72 ,  C07H15/252 ,  G01N33/57426 ,  G01N33/57434

摘要： The instant invention provides reagents and methods for diagnosis, detection and treatment of cancers (for example, prostate cancers). In particular, the invention provides methods to generate various functionalized PSMA ligands, and their uses in diagnosis, detection, imaging, and treatment of prostate cancers, especially those overexpressing PSMA.

摘要翻译： 本发明提供用于癌症（例如前列腺癌）的诊断，检测和治疗的试剂和方法。 特别地，本发明提供了生成各种官能化PSMA配体的方法及其在诊断，检测，成像和治疗前列腺癌，特别是过表达PSMA的那些中的用途。